美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

信息服務

4.17

+0.07001.71%

盤前：4.300.1300+3.12%07:54 EDT

成交量：15.41萬

成交額：63.82萬

市值：2.00億

市盈率：21.92

高：4.18

開：4.10

低：4.08

收：4.10

52周最高：6.45

52周最低：3.51

股本：4,788.41萬

流通股本：3,423.30萬

量比：0.75

換手率：0.45%

股息：0.18

股息率：4.32%

每股收益(TTM):0.1903

每股收益(LYR):0.1900

淨資產收益率：9.78%

總資產收益率：5.35%

市淨率：2.11

市盈率(LYR):21.95

資料載入中...

總覽公司新聞資訊公告

天壇生物旗下成都蓉生重組八因子新藥啓動III期臨床

G-III服裝集團盤中異動下午盤大幅下挫5.00%報30.01美元

阿斯利康甲磺酸奧希替尼片啓動II期臨床適應症為不適合或拒絕化療的EGFR常見突變陽性III期不可切除NSCLC患者

港股異動 | 諾誠健華(09969)升逾4% 自研新型TYK2抑制劑ICP-332治療CSU獲批准開展II/III期臨床試驗

新諾威(300765.SZ)子公司司庫奇尤單抗注射液III期臨床試驗獲得頂線分析數據

登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨床研究結果背靠背同步發表

III期ARTISTRY-2研究達主要終點，吉利德新型HIV二聯療法展現潛力

來凱醫藥-B(02105)：LAE002 (AFURESERTIB)針對HR+/HER2-局部晚期或轉移性乳腺癌的III期臨床試驗(AFFIRM-205)已完成入組

復星醫藥控股子公司酮洛芬貼劑獲准開展III期臨床試驗

2025年11月貴州省互聯網新聞信息服務單位新增、變更新聞信息服務許可事項

多彩贵州网

【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發，最佳MRD陰性完全緩解率超60%

信達生物信美悦（匹康奇拜單抗注射液）一項新臨床III期研究（CLEAR-2）達成終點，為中重度銀屑病長期管理提供更優方案

中慧生物-B(02627)：凍幹人用狂犬病疫苗(人二倍體細胞)的III期臨床試驗啓動

脱髮新藥III期成功；創新藥出海新模式誕生

勁方醫藥-B(02595)：GFH375治療轉移性胰腺癌註冊性臨床試驗在首家研究中心啓動為全球首個口服KRAS G12D抑制劑單藥對照化療III期研究

亞盛醫藥-B(06855)耐立克®一線治療Ph+ ALL的全球註冊III期臨床研究獲美國FDA和歐洲EMA批准

CSLM Digital Asset Acquisition Corp III, Ltd. (Nasdaq: KOYN) 與 First Digital Group Ltd. 宣佈就擬議業務合併簽署意向書，以此打造全球穩定幣與數字支付領軍企業

君聖泰醫藥-B(02511)公布HTD1801與達格列淨的頭對頭III期臨床研究結果展現控糖優勢及心血管代謝優效獲益

東誠藥業(002675.SZ)：氟[18F]思睿肽注射液完成III期臨床試驗

智通财经网

港股異動 | 宜明昂科-B(01541)午後升逾9% IMM0306的III期臨床研究方案獲CDE許可

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/III/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"III","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服務","latestPrice":4.17,"timestamp":1776369600000,"preClose":4.1,"halted":0,"volume":154129,"hourTrading":{"tag":"盘前","latestPrice":4.3,"preClose":4.17,"latestTime":"07:54 EDT","volume":520,"amount":2232.00016,"timestamp":1776426874830,"change":0.13,"changeRate":0.031175,"amplitude":0.004796},"delay":0,"changeRate":0.017073170731707388,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"盤前交易","change":0.07,"latestTime":"04-17 07:59:29 EDT","open":4.1,"high":4.175,"low":4.08,"amount":638209.7184016,"amplitude":0.023171,"askPrice":4.5,"askSize":298,"bidPrice":3.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776432600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.17,"dividendRate":0.043165,"preHourTrading":{"tag":"盘前","latestPrice":4.3,"preClose":4.17,"latestTime":"07:54 EDT","volume":520,"amount":2232.00016,"timestamp":1776426874830,"change":0.13,"changeRate":0.031175,"amplitude":0.004796},"postHourTrading":{"tag":"盘后","latestPrice":4.3,"preClose":4.17,"latestTime":"19:56 EDT","volume":685,"amount":2879.264,"timestamp":1776383788282,"change":0.13,"changeRate":0.031175,"amplitude":0.031175},"volumeRatio":0.752013481102453,"impliedVol":1.9099,"impliedVolPercentile":0.8795},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","floatShares":34233044,"roa":"5.35%","roe":"9.78%","lyrEps":0.19,"volumeRatio":0.752013481102453,"shares":47884104,"dividePrice":0.18,"high":4.175,"amplitude":0.023171,"preClose":4.1,"low":4.08,"week52Low":3.51,"pbRate":"2.11","psRate":"0.82","week52High":6.4495,"institutionHeld":0.6844,"latestPrice":4.17,"committee":-0.497487,"eps":0.190275,"divideRate":0.043165,"volume":154129,"delay":0,"ttmEps":0.190275,"open":4.1,"prevYearClose":5.78,"prevWeekClose":3.94,"prevMonthClose":3.84,"prevQuarterClose":3.84,"fiveDayClose":4,"twentyDayClose":3.91,"sixtyDayClose":5.58,"earningDate":1778083200000,"earningTime":"盘后","dividendPayoutRate":0.9280598907982862,"dividendFrequency":"Q","dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.03333720106347336},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/III\",params:#limit:5,,,undefined,":[{"date":"2026-05-07","symbol":"III","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/03","expectedEps":0.05,"defaultRemindTime":1778184000000,"name":null,"time":"盤後","dateTimestamp":1778126400000,"actualEps":null},{"date":"2026-03-20","symbol":"III","amount":0.045,"announcedDate":"2026-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-26"},{"market":"US","date":"2026-03-05","symbol":"III","fiscalQuarterEnding":"2025/12","expectedEps":0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":0.06},{"date":"2025-12-05","symbol":"III","amount":0.045,"announcedDate":"2025-11-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-05","defaultRemindTime":1764945000000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-05","currency":"USD","dateTimestamp":1764910800000,"payDate":"2025-12-19"},{"market":"US","date":"2025-11-03","symbol":"III","fiscalQuarterEnding":"2025/09","expectedEps":0.06,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762146000000,"reportTimeType":"pre","actualEps":0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"III\",market:\"US\",,,undefined,":[{"executeDate":"2021-06-03","recordDate":"2021-06-04","paymentDate":"2021-06-18","value":0.03,"currency":"USD"},{"executeDate":"2021-09-03","recordDate":"2021-09-07","paymentDate":"2021-09-24","value":0.03,"currency":"USD"},{"executeDate":"2021-12-02","recordDate":"2021-12-03","paymentDate":"2021-12-17","value":0.03,"currency":"USD"},{"executeDate":"2022-03-18","recordDate":"2022-03-21","paymentDate":"2022-04-06","value":0.03,"currency":"USD"},{"executeDate":"2022-06-02","recordDate":"2022-06-03","paymentDate":"2022-06-17","value":0.04,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"III\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1679457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/III\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"III","date":"2026-04-15","current":21.915648,"percent":0.544715,"low":-221.876594,"twenty":12.58915,"median":18.866214,"eighty":31.39051,"high":85.733259,"avg":2.746404,"sd":59.959219,"marketCap":194034567},"quantilePoints":[{"date":"2021-04-16","current":76.422065,"twenty":27.379781,"median":34.193624,"eighty":53.109266,"marketCap":210542788},{"date":"2021-04-23","current":77.124796,"twenty":27.464698,"median":34.23369,"eighty":53.271145,"marketCap":212478813},{"date":"2021-04-30","current":79.935723,"twenty":27.596809,"median":34.39907,"eighty":53.663807,"marketCap":220222916},{"date":"2021-05-07","current":85.733259,"twenty":27.758845,"median":34.72983,"eighty":53.929654,"marketCap":236195128},{"date":"2021-05-14","current":34.582604,"twenty":27.90985,"median":34.72983,"eighty":53.929654,"marketCap":260718251},{"date":"2021-05-21","current":37.193814,"twenty":27.984267,"median":34.89521,"eighty":53.929654,"marketCap":280404160},{"date":"2021-05-28","current":37.32119,"twenty":28.127158,"median":35.060591,"eighty":53.929654,"marketCap":281364448},{"date":"2021-06-04","current":35.665301,"twenty":28.201568,"median":35.178625,"eighty":53.929654,"marketCap":268880701},{"date":"2021-06-11","current":36.811685,"twenty":28.275979,"median":35.34686,"eighty":53.929654,"marketCap":277523295},{"date":"2021-06-18","current":35.283172,"twenty":28.317177,"median":35.460054,"eighty":53.929654,"marketCap":265999836},{"date":"2021-06-25","current":35.983741,"twenty":28.42477,"median":35.600769,"eighty":53.929654,"marketCap":271281422},{"date":"2021-07-02","current":38.27651,"twenty":28.559204,"median":35.741483,"eighty":53.929654,"marketCap":288566610},{"date":"2021-07-09","current":38.212822,"twenty":28.661781,"median":35.920053,"eighty":53.929654,"marketCap":288086466},{"date":"2021-07-16","current":36.174805,"twenty":28.841499,"median":36.238493,"eighty":53.929654,"marketCap":272721854},{"date":"2021-07-23","current":38.085446,"twenty":29.02216,"median":36.365869,"eighty":53.929654,"marketCap":287126177},{"date":"2021-07-30","current":38.021758,"twenty":29.112158,"median":36.556933,"eighty":53.929654,"marketCap":286646033},{"date":"2021-08-06","current":37.830694,"twenty":29.227833,"median":36.811685,"eighty":53.929654,"marketCap":285205601},{"date":"2021-08-13","current":30.04792,"twenty":29.342728,"median":36.811685,"eighty":53.929654,"marketCap":331488657},{"date":"2021-08-20","current":29.125396,"twenty":29.392136,"median":36.811685,"eighty":53.929654,"marketCap":321311374},{"date":"2021-08-27","current":31.014374,"twenty":29.446637,"median":36.811685,"eighty":53.929654,"marketCap":342150573},{"date":"2021-09-03","current":32.376195,"twenty":29.490206,"median":36.811685,"eighty":53.929654,"marketCap":357174181},{"date":"2021-09-10","current":33.869805,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":373651688},{"date":"2021-09-17","current":33.210859,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":366382200},{"date":"2021-09-24","current":32.859422,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":362505139},{"date":"2021-10-01","current":31.936898,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":352327856},{"date":"2021-10-08","current":33.386578,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-15","current":31.849038,"twenty":29.673426,"median":36.811685,"eighty":53.929654,"marketCap":351358591},{"date":"2021-10-22","current":33.386578,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-29","current":35.802712,"twenty":29.76934,"median":36.811685,"eighty":53.929654,"marketCap":394975520},{"date":"2021-11-05","current":32.443868,"twenty":29.838435,"median":36.811685,"eighty":53.929654,"marketCap":434715388},{"date":"2021-11-12","current":34.955794,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":468372678},{"date":"2021-11-19","current":34.77297,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":465923030},{"date":"2021-11-26","current":30.348649,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":406641551},{"date":"2021-12-03","current":28.886064,"twenty":29.82833,"median":36.811685,"eighty":53.929654,"marketCap":387044368},{"date":"2021-12-10","current":29.507663,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":395373171},{"date":"2021-12-17","current":26.984703,"twenty":29.661234,"median":36.811685,"eighty":53.929654,"marketCap":361568030},{"date":"2021-12-23","current":28.081642,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":376265917},{"date":"2021-12-31","current":27.862254,"twenty":29.504246,"median":36.811685,"eighty":53.929654,"marketCap":373326339},{"date":"2022-01-07","current":26.399668,"twenty":29.437039,"median":36.760945,"eighty":53.927618,"marketCap":353729156},{"date":"2022-01-14","current":25.302729,"twenty":29.255815,"median":36.760945,"eighty":53.927618,"marketCap":339031269},{"date":"2022-01-21","current":23.145416,"twenty":29.125104,"median":36.760945,"eighty":53.927618,"marketCap":310125424},{"date":"2022-01-28","current":22.670075,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":303756339},{"date":"2022-02-04","current":24.863954,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":333152114},{"date":"2022-02-11","current":25.887763,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":346870142},{"date":"2022-02-18","current":27.130961,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":363527748},{"date":"2022-02-25","current":26.107151,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":349809720},{"date":"2022-03-04","current":27.423478,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":367447185},{"date":"2022-03-11","current":22.999463,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":357158663},{"date":"2022-03-18","current":22.63323,"twenty":28.930434,"median":36.760945,"eighty":53.927618,"marketCap":351471428},{"date":"2022-03-25","current":21.138876,"twenty":28.720555,"median":36.760945,"eighty":53.927618,"marketCap":328265612},{"date":"2022-04-01","current":21.387935,"twenty":28.563876,"median":36.760945,"eighty":53.927618,"marketCap":332133248},{"date":"2022-04-08","current":20.640759,"twenty":28.47654,"median":36.760945,"eighty":53.927618,"marketCap":320530340},{"date":"2022-04-14","current":20.79642,"twenty":28.362763,"median":36.760945,"eighty":53.927618,"marketCap":322947612},{"date":"2022-04-22","current":19.769052,"twenty":28.214177,"median":36.760945,"eighty":53.927618,"marketCap":306993613},{"date":"2022-04-29","current":19.519993,"twenty":28.004454,"median":36.760945,"eighty":53.927618,"marketCap":303125977},{"date":"2022-05-06","current":18.430361,"twenty":27.931066,"median":36.760945,"eighty":53.927618,"marketCap":286205069},{"date":"2022-05-13","current":17.907825,"twenty":27.846885,"median":36.556933,"eighty":53.927618,"marketCap":305059795},{"date":"2022-05-20","current":17.625134,"twenty":27.555111,"median":36.381032,"eighty":53.927618,"marketCap":300244158},{"date":"2022-05-27","current":18.472496,"twenty":27.379781,"median":36.238493,"eighty":53.927618,"marketCap":314678973},{"date":"2022-06-03","current":18.274778,"twenty":27.167526,"median":36.092994,"eighty":53.927618,"marketCap":311310849},{"date":"2022-06-10","current":16.269354,"twenty":26.614253,"median":35.829538,"eighty":53.927618,"marketCap":277148453},{"date":"2022-06-17","current":16.551809,"twenty":26.372596,"median":35.640231,"eighty":53.822908,"marketCap":281960058},{"date":"2022-06-24","current":17.879343,"twenty":26.107151,"median":35.537925,"eighty":53.79462,"marketCap":304574602},{"date":"2022-07-01","current":19.093895,"twenty":25.975518,"median":35.458953,"eighty":53.271145,"marketCap":325264504},{"date":"2022-07-08","current":19.856521,"twenty":25.412423,"median":35.283172,"eighty":53.041064,"marketCap":338255838},{"date":"2022-07-15","current":19.291613,"twenty":24.849328,"median":35.178625,"eighty":52.906055,"marketCap":328632628},{"date":"2022-07-22","current":20.138975,"twenty":24.08147,"median":35.060591,"eighty":52.665026,"marketCap":343067443},{"date":"2022-07-29","current":21.071074,"twenty":23.209281,"median":34.955794,"eighty":52.523833,"marketCap":358945740},{"date":"2022-08-05","current":21.635982,"twenty":22.947966,"median":34.77297,"eighty":52.322009,"marketCap":368568950},{"date":"2022-08-12","current":16.409925,"twenty":22.628286,"median":34.72983,"eighty":52.322009,"marketCap":293507911},{"date":"2022-08-19","current":16.552576,"twenty":22.371718,"median":34.475053,"eighty":52.322009,"marketCap":296059374},{"date":"2022-08-26","current":16.15211,"twenty":21.544722,"median":34.282985,"eighty":52.322009,"marketCap":288896647},{"date":"2022-09-02","current":14.950714,"twenty":21.183009,"median":34.23369,"eighty":52.322009,"marketCap":267408467},{"date":"2022-09-09","current":14.817225,"twenty":21.074397,"median":34.193624,"eighty":52.322009,"marketCap":265020891},{"date":"2022-09-16","current":14.123085,"twenty":20.842582,"median":34.06831,"eighty":52.322009,"marketCap":252605498},{"date":"2022-09-23","current":12.948386,"twenty":20.628306,"median":33.98562,"eighty":52.322009,"marketCap":231594833},{"date":"2022-09-30","current":12.708107,"twenty":20.189817,"median":33.90293,"eighty":52.322009,"marketCap":227297197},{"date":"2022-10-07","current":12.761502,"twenty":19.975152,"median":33.869805,"eighty":52.322009,"marketCap":228252227},{"date":"2022-10-14","current":12.814898,"twenty":19.650749,"median":33.737549,"eighty":52.322009,"marketCap":229207257},{"date":"2022-10-21","current":13.268758,"twenty":19.370558,"median":33.630766,"eighty":52.322009,"marketCap":237325014},{"date":"2022-10-28","current":14.790528,"twenty":19.172983,"median":33.57217,"eighty":52.322009,"marketCap":264543376},{"date":"2022-11-04","current":11.924698,"twenty":18.940931,"median":33.57217,"eighty":52.322009,"marketCap":226819682},{"date":"2022-11-11","current":14.156908,"twenty":18.67839,"median":33.490051,"eighty":52.100253,"marketCap":269278547},{"date":"2022-11-18","current":14.055967,"twenty":18.383013,"median":33.406789,"eighty":51.591958,"marketCap":267358557},{"date":"2022-11-25","current":13.52603,"twenty":17.941577,"median":33.349337,"eighty":51.184669,"marketCap":257278611},{"date":"2022-12-02","current":13.223208,"twenty":17.811433,"median":33.272057,"eighty":50.857754,"marketCap":251518642},{"date":"2022-12-09","current":12.59233,"twenty":17.329516,"median":33.261363,"eighty":50.482919,"marketCap":239518707},{"date":"2022-12-16","current":11.406279,"twenty":16.879455,"median":33.138265,"eighty":50.207132,"marketCap":216958829},{"date":"2022-12-23","current":11.507219,"twenty":16.612253,"median":33.07907,"eighty":49.781169,"marketCap":218878818},{"date":"2022-12-30","current":11.60816,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":220798808},{"date":"2023-01-06","current":12.264273,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":233278741},{"date":"2023-01-13","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-01-20","current":12.970857,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246718668},{"date":"2023-01-27","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-02-03","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-10","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-17","current":13.677441,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":260158596},{"date":"2023-02-24","current":12.945622,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246238671},{"date":"2023-03-03","current":13.500795,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":256798614},{"date":"2023-03-10","current":12.166618,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239998705},{"date":"2023-03-17","current":11.411218,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":225097683},{"date":"2023-03-24","current":12.147425,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239620114},{"date":"2023-03-31","current":12.490989,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":246397249},{"date":"2023-04-06","current":12.294667,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":242524601},{"date":"2023-04-14","current":12.687311,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":250269897},{"date":"2023-04-21","current":12.270127,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":242040520},{"date":"2023-04-28","current":12.196506,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":240588276},{"date":"2023-05-05","current":12.245586,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":241556438},{"date":"2023-05-12","current":13.473902,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":246397249},{"date":"2023-05-19","current":14.20765,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":259815303},{"date":"2023-05-26","current":13.413927,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":245300481},{"date":"2023-06-02","current":13.387469,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":244816654},{"date":"2023-06-09","current":13.943076,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":254977029},{"date":"2023-06-16","current":14.075363,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":257396166},{"date":"2023-06-23","current":15.080746,"twenty":16.529212,"median":33.076029,"eighty":49.624683,"marketCap":275781606},{"date":"2023-06-30","current":14.154735,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":258847648},{"date":"2023-07-07","current":13.810789,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":252557892},{"date":"2023-07-14","current":14.260565,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":260782957},{"date":"2023-07-21","current":14.048906,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":256912338},{"date":"2023-07-28","current":13.387469,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":244816654},{"date":"2023-08-04","current":16.278939,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":254977029},{"date":"2023-08-11","current":16.275803,"twenty":16.382336,"median":32.997393,"eighty":49.558778,"marketCap":254927904},{"date":"2023-08-18","current":15.376759,"twenty":16.278939,"median":32.930248,"eighty":49.391703,"marketCap":240846172},{"date":"2023-08-25","current":15.40776,"twenty":16.232204,"median":32.835614,"eighty":49.042233,"marketCap":241331749},{"date":"2023-09-01","current":16.120795,"twenty":16.15211,"median":32.803437,"eighty":48.925743,"marketCap":252500019},{"date":"2023-09-08","current":15.035742,"twenty":16.031821,"median":32.75433,"eighty":48.809254,"marketCap":235504825},{"date":"2023-09-15","current":14.446713,"twenty":15.779779,"median":32.64723,"eighty":48.576274,"marketCap":226278863},{"date":"2023-09-22","current":13.733678,"twenty":15.562768,"median":32.609831,"eighty":48.459784,"marketCap":215110593},{"date":"2023-09-29","current":13.423662,"twenty":15.404575,"median":32.491023,"eighty":48.459784,"marketCap":210254823},{"date":"2023-10-06","current":13.950688,"twenty":15.345757,"median":32.431996,"eighty":48.459784,"marketCap":218509632},{"date":"2023-10-13","current":13.361659,"twenty":15.080746,"median":32.334816,"eighty":48.343294,"marketCap":209283669},{"date":"2023-10-20","current":13.051644,"twenty":14.911736,"median":32.178609,"eighty":48.324535,"marketCap":204427900},{"date":"2023-10-27","current":12.77263,"twenty":14.827387,"median":32.156546,"eighty":48.226804,"marketCap":200057707},{"date":"2023-11-03","current":15.032891,"twenty":14.614323,"median":32.100506,"eighty":48.180208,"marketCap":200057707},{"date":"2023-11-10","current":15.314305,"twenty":14.614323,"median":32.044484,"eighty":48.063719,"marketCap":203802770},{"date":"2023-11-17","current":15.975354,"twenty":14.614323,"median":32.022403,"eighty":47.932458,"marketCap":212600012},{"date":"2023-11-24","current":16.048804,"twenty":14.614323,"median":31.943078,"eighty":47.714249,"marketCap":213577483},{"date":"2023-12-01","current":15.27758,"twenty":14.614323,"median":31.841671,"eighty":47.187487,"marketCap":203314034},{"date":"2023-12-08","current":16.673128,"twenty":14.619662,"median":31.750721,"eighty":46.490677,"marketCap":221885989},{"date":"2023-12-15","current":16.673128,"twenty":14.619662,"median":31.53949,"eighty":46.22662,"marketCap":221885989},{"date":"2023-12-22","current":17.407627,"twenty":14.619662,"median":31.467912,"eighty":45.230776,"marketCap":231660702},{"date":"2023-12-29","current":17.554527,"twenty":14.614323,"median":31.234022,"eighty":45.040598,"marketCap":233615645},{"date":"2024-01-05","current":16.673128,"twenty":14.608983,"median":31.080268,"eighty":44.740412,"marketCap":221885989},{"date":"2024-01-12","current":16.452778,"twenty":14.608983,"median":30.97496,"eighty":44.593596,"marketCap":218953575},{"date":"2024-01-19","current":16.269154,"twenty":14.603644,"median":30.818124,"eighty":44.593596,"marketCap":216509897},{"date":"2024-01-26","current":17.554527,"twenty":14.608983,"median":30.62605,"eighty":44.463847,"marketCap":233615645},{"date":"2024-02-02","current":16.820028,"twenty":14.608983,"median":30.523385,"eighty":44.220503,"marketCap":223840932},{"date":"2024-02-09","current":16.122254,"twenty":14.608983,"median":30.418362,"eighty":43.923358,"marketCap":214554954},{"date":"2024-02-16","current":16.305879,"twenty":14.608983,"median":30.260593,"eighty":43.769861,"marketCap":216998633},{"date":"2024-02-23","current":15.608105,"twenty":14.608983,"median":30.141793,"eighty":42.75327,"marketCap":207712655},{"date":"2024-03-01","current":15.901904,"twenty":14.614323,"median":30.092043,"eighty":42.030433,"marketCap":211622540},{"date":"2024-03-08","current":34.784891,"twenty":14.614323,"median":29.930691,"eighty":41.395649,"marketCap":214066219},{"date":"2024-03-15","current":30.710223,"twenty":14.614323,"median":29.930691,"eighty":41.308941,"marketCap":188990710},{"date":"2024-03-22","current":32.281078,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":198657754},{"date":"2024-03-28","current":31.652736,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":194790936},{"date":"2024-04-05","current":31.966907,"twenty":14.608983,"median":30.092453,"eighty":41.339259,"marketCap":196724345},{"date":"2024-04-12","current":30.238966,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":186090597},{"date":"2024-04-19","current":28.589568,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":175940200},{"date":"2024-04-26","current":27.411426,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":168689917},{"date":"2024-05-03","current":26.39037,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":162406339},{"date":"2024-05-10","current":25.919114,"twenty":14.614323,"median":30.117759,"eighty":41.308941,"marketCap":159506226},{"date":"2024-05-17","current":-211.151442,"twenty":14.503289,"median":29.916131,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-24","current":-211.151442,"twenty":14.319403,"median":29.768426,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-31","current":-216.514018,"twenty":14.260565,"median":29.603046,"eighty":41.308941,"marketCap":157189177},{"date":"2024-06-07","current":-209.810798,"twenty":14.204967,"median":29.476834,"eighty":41.308941,"marketCap":152322639},{"date":"2024-06-14","current":-212.492085,"twenty":14.156908,"median":29.278446,"eighty":41.339259,"marketCap":154269254},{"date":"2024-06-21","current":-203.777899,"twenty":14.123085,"median":28.941526,"eighty":41.369578,"marketCap":147942755},{"date":"2024-06-28","current":-205.788865,"twenty":14.101821,"median":28.815898,"eighty":41.369578,"marketCap":149402716},{"date":"2024-07-05","current":-205.118543,"twenty":14.061456,"median":28.592041,"eighty":41.369578,"marketCap":148916062},{"date":"2024-07-12","current":-210.48112,"twenty":13.995991,"median":28.46557,"eighty":41.369578,"marketCap":152809293},{"date":"2024-07-15","current":-211.151442,"twenty":13.995991,"median":28.446337,"eighty":41.369578,"marketCap":153295947},{"date":"2024-08-02","current":-221.876594,"twenty":13.965764,"median":28.594514,"eighty":41.395649,"marketCap":161082407},{"date":"2024-08-09","current":-155.153276,"twenty":13.890161,"median":28.447288,"eighty":41.369578,"marketCap":158411495},{"date":"2024-08-16","current":-157.547617,"twenty":13.879322,"median":28.196854,"eighty":41.040322,"marketCap":160856117},{"date":"2024-08-23","current":-158.026486,"twenty":13.823503,"median":28.008512,"eighty":39.690077,"marketCap":161345042},{"date":"2024-08-30","current":-166.167244,"twenty":13.795681,"median":27.935383,"eighty":38.544,"marketCap":169656756},{"date":"2024-09-06","current":-154.195541,"twenty":13.753035,"median":27.569737,"eighty":38.347232,"marketCap":157433647},{"date":"2024-09-13","current":-151.322331,"twenty":13.704502,"median":27.313784,"eighty":38.122137,"marketCap":154500100},{"date":"2024-09-20","current":-156.111013,"twenty":13.672394,"median":27.130961,"eighty":37.980944,"marketCap":159389344},{"date":"2024-09-27","current":-154.195541,"twenty":13.62697,"median":26.595041,"eighty":37.894382,"marketCap":157433647},{"date":"2024-10-04","current":-155.153276,"twenty":13.599214,"median":26.468913,"eighty":37.779744,"marketCap":158411495},{"date":"2024-10-11","current":-150.364595,"twenty":13.553316,"median":26.233285,"eighty":37.589923,"marketCap":153522252},{"date":"2024-10-18","current":-152.280068,"twenty":13.524775,"median":26.107151,"eighty":37.433759,"marketCap":155477949},{"date":"2024-10-25","current":-147.012518,"twenty":13.48942,"median":25.919114,"eighty":37.27024,"marketCap":150099781},{"date":"2024-10-31","current":-150.364595,"twenty":13.450324,"median":25.485552,"eighty":37.015362,"marketCap":153522252},{"date":"2024-11-08","current":-52.964156,"twenty":13.423662,"median":24.845672,"eighty":36.750798,"marketCap":162811815},{"date":"2024-11-15","current":-53.318651,"twenty":13.387469,"median":24.004684,"eighty":36.556933,"marketCap":163901532},{"date":"2024-11-22","current":-53.238832,"twenty":13.341574,"median":23.198637,"eighty":36.327656,"marketCap":163656170},{"date":"2024-11-29","current":-58.905934,"twenty":13.314055,"median":22.981027,"eighty":36.238493,"marketCap":181076842},{"date":"2024-12-06","current":-58.267387,"twenty":13.27171,"median":22.651653,"eighty":35.999189,"marketCap":179113949},{"date":"2024-12-13","current":-58.427024,"twenty":13.239501,"median":22.455197,"eighty":35.783905,"marketCap":179604672},{"date":"2024-12-20","current":-55.074654,"twenty":13.19425,"median":21.621859,"eighty":35.607032,"marketCap":169299486},{"date":"2024-12-27","current":-53.957197,"twenty":13.130069,"median":21.342486,"eighty":35.505726,"marketCap":165864424},{"date":"2025-01-03","current":-51.88192,"twenty":13.070245,"median":21.138876,"eighty":35.459393,"marketCap":159485023},{"date":"2025-01-10","current":-49.96628,"twenty":13.021327,"median":20.901601,"eighty":35.211692,"marketCap":153596345},{"date":"2025-01-17","current":-51.88192,"twenty":12.972548,"median":20.664813,"eighty":35.117714,"marketCap":159485023},{"date":"2025-01-24","current":-51.562647,"twenty":12.952487,"median":20.578494,"eighty":35.032487,"marketCap":158503577},{"date":"2025-01-31","current":-49.168097,"twenty":12.915203,"median":20.138975,"eighty":34.93156,"marketCap":151142730},{"date":"2025-02-07","current":-51.083737,"twenty":12.802486,"median":19.831317,"eighty":34.780123,"marketCap":157031408},{"date":"2025-02-14","current":-51.40301,"twenty":12.725025,"median":19.519993,"eighty":34.72983,"marketCap":158012854},{"date":"2025-02-21","current":-49.48737,"twenty":12.667751,"median":19.333199,"eighty":34.575342,"marketCap":152124176},{"date":"2025-02-28","current":-49.00846,"twenty":12.601316,"median":19.122141,"eighty":34.324158,"marketCap":150652007},{"date":"2025-03-07","current":53.583718,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":152124176},{"date":"2025-03-14","current":56.52218,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":160466470},{"date":"2025-03-21","current":63.229713,"twenty":12.589786,"median":18.928478,"eighty":34.39907,"marketCap":179509154},{"date":"2025-03-28","current":64.079574,"twenty":12.589786,"median":18.928478,"eighty":34.546571,"marketCap":181921911},{"date":"2025-04-04","current":63.569657,"twenty":12.589786,"median":18.928478,"eighty":34.686729,"marketCap":180474257},{"date":"2025-04-11","current":60.17021,"twenty":12.590422,"median":18.990743,"eighty":34.733776,"marketCap":170823227},{"date":"2025-04-17","current":62.889768,"twenty":12.590422,"median":18.990743,"eighty":34.814432,"marketCap":178544051},{"date":"2025-04-25","current":62.379851,"twenty":12.589786,"median":18.928478,"eighty":34.943677,"marketCap":177096396},{"date":"2025-05-02","current":64.589491,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":183369566},{"date":"2025-05-09","current":25.015629,"twenty":12.589786,"median":18.928478,"eighty":35.046539,"marketCap":193020596},{"date":"2025-05-16","current":29.987043,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":231380025},{"date":"2025-05-23","current":29.29984,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":226077566},{"date":"2025-05-30","current":29.237367,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":225595524},{"date":"2025-06-06","current":29.424786,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":227041650},{"date":"2025-06-13","current":29.862097,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":230415942},{"date":"2025-06-20","current":29.612205,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":228487775},{"date":"2025-06-27","current":28.862529,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":222703274},{"date":"2025-07-03","current":31.923706,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":246323318},{"date":"2025-07-11","current":31.486395,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":242949026},{"date":"2025-07-18","current":29.237367,"twenty":12.58915,"median":18.866214,"eighty":34.89521,"marketCap":225595524},{"date":"2025-07-25","current":28.425218,"twenty":12.58915,"median":18.866214,"eighty":34.834126,"marketCap":219328982},{"date":"2025-08-01","current":26.925866,"twenty":12.58915,"median":18.866214,"eighty":34.784891,"marketCap":207759981},{"date":"2025-08-08","current":25.754678,"twenty":12.58915,"median":18.866214,"eighty":34.77297,"marketCap":202457522},{"date":"2025-08-15","current":30.470866,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":239531480},{"date":"2025-08-22","current":29.489913,"twenty":12.58915,"median":18.866214,"eighty":34.221243,"marketCap":231820205},{"date":"2025-08-29","current":31.39051,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":246760801},{"date":"2025-09-05","current":32.432773,"twenty":12.58915,"median":18.85295,"eighty":34.118522,"marketCap":254954031},{"date":"2025-09-12","current":32.126225,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":252544257},{"date":"2025-09-19","current":33.965513,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":267002898},{"date":"2025-09-26","current":35.314324,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":277605901},{"date":"2025-10-03","current":34.639918,"twenty":12.58915,"median":18.866214,"eighty":34.639918,"marketCap":272304399},{"date":"2025-10-10","current":33.842894,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":266038988},{"date":"2025-10-17","current":33.413727,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":262665306},{"date":"2025-10-24","current":34.088132,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":267966807},{"date":"2025-10-31","current":33.536346,"twenty":12.58915,"median":18.866214,"eighty":34.748399,"marketCap":263629215},{"date":"2025-11-07","current":28.380485,"twenty":12.58915,"median":18.866214,"eighty":34.701228,"marketCap":277248962},{"date":"2025-11-14","current":25.733601,"twenty":12.58915,"median":18.866214,"eighty":34.517299,"marketCap":251391546},{"date":"2025-11-21","current":24.557208,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":239899361},{"date":"2025-11-28","current":26.370814,"twenty":12.58915,"median":18.866214,"eighty":34.210751,"marketCap":257616479},{"date":"2025-12-05","current":28.282453,"twenty":12.58915,"median":18.866214,"eighty":33.965513,"marketCap":276291280},{"date":"2025-12-12","current":29.409829,"twenty":12.58915,"median":18.866214,"eighty":33.842894,"marketCap":287304624},{"date":"2025-12-19","current":29.26278,"twenty":12.58915,"median":18.866214,"eighty":33.529773,"marketCap":285868100},{"date":"2025-12-26","current":29.066715,"twenty":12.58915,"median":18.866214,"eighty":33.430508,"marketCap":283952736},{"date":"2026-01-02","current":28.331469,"twenty":12.58915,"median":18.866214,"eighty":33.342648,"marketCap":276770121},{"date":"2026-01-09","current":29.164747,"twenty":12.58915,"median":18.866214,"eighty":33.210859,"marketCap":284910418},{"date":"2026-01-16","current":29.80196,"twenty":12.58915,"median":18.866214,"eighty":33.054432,"marketCap":291135352},{"date":"2026-01-23","current":27.792289,"twenty":12.58915,"median":18.866214,"eighty":32.903351,"marketCap":271502869},{"date":"2026-01-30","current":27.400158,"twenty":12.58915,"median":18.866214,"eighty":32.739321,"marketCap":267672141},{"date":"2026-02-06","current":24.998355,"twenty":12.58915,"median":18.866214,"eighty":32.548436,"marketCap":244208930},{"date":"2026-02-13","current":22.35147,"twenty":12.58915,"median":18.866214,"eighty":32.359621,"marketCap":218351514},{"date":"2026-02-20","current":22.841634,"twenty":12.58915,"median":18.866214,"eighty":32.126225,"marketCap":223139924},{"date":"2026-02-27","current":23.429831,"twenty":12.58915,"median":18.866214,"eighty":32.068687,"marketCap":228886017},{"date":"2026-03-06","current":24.400849,"twenty":12.58915,"median":18.866214,"eighty":31.936898,"marketCap":227928335},{"date":"2026-03-13","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.809821,"marketCap":191174107},{"date":"2026-03-20","current":19.649525,"twenty":12.58915,"median":18.866214,"eighty":31.731279,"marketCap":183546212},{"date":"2026-03-27","current":19.7516,"twenty":12.58915,"median":18.866214,"eighty":31.635749,"marketCap":184499699},{"date":"2026-04-02","current":19.598487,"twenty":12.58915,"median":18.866214,"eighty":31.486395,"marketCap":183069469},{"date":"2026-04-10","current":20.415091,"twenty":12.58915,"median":18.866214,"eighty":31.417108,"marketCap":190697364},{"date":"2026-04-15","current":20.772355,"twenty":12.58915,"median":18.866214,"eighty":31.39051,"marketCap":194034567}],"updateTime":1776395868998},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"III\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592811181","title":"天壇生物旗下成都蓉生重組八因子新藥啓動III期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2592811181","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592811181?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 10:42","pubTimestamp":1766198535,"startTime":"0","endTime":"0","summary":"中访网数据  北京天坛生物制品股份有限公司今日公告，其下属企业成都蓉生药业有限责任公司研发的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”已于近日正式启动III期临床试验。该药品注册分类为治疗用生物制品，拟用于A型血友病患者的出血控制、预防及手术出血预防。根据公告，该产品研发累计投入已达9868.32万元。目前，国内市场尚无同类产品上市，国际市场主要有赛诺菲公司的Eloctate和Altuviiio两款产品。该药品后续仍需完成III期临床试验、提交上市申请并通过国家药监部门审评审批，方可实现上市销售。天坛生物提示，药品研发周期长且存在不确定性，投资者需注意相关风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251220/31879523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0010","BK0028","600161","BK0168","III","BK0188","BK0185","BK0082","BK4134","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592146209","title":"G-III服裝集團盤中異動 下午盤大幅下挫5.00%報30.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592146209?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 04:27","pubTimestamp":1766176076,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日04时27分，G-III服装集团股票出现异动，股价快速跳水5.00%。截至发稿，该股报30.01美元/股，成交量27.949万股，换手率0.66%，振幅4.75%。G-III服装集团股票所在的服装制造行业中，整体跌幅为1.21%。其相关个股中，文斯控股、兰亭集势、Xcel Brands, Inc涨幅较大，儿童之家、金铉集团、雷克兰医疗工业较为活跃，换手率分别为4.78%、3.71%、3.11%，振幅较大的相关个股有文斯控股、兰亭集势、金铉集团，振幅分别为14.49%、14.13%、13.31%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122004275697a080a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122004275697a080a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","BK4202","GIII","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592199939","title":"阿斯利康甲磺酸奧希替尼片啓動II期臨床 適應症為不適合或拒絕化療的EGFR常見突變陽性III期不可切除NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199939","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592199939?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 18:03","pubTimestamp":1766138580,"startTime":"0","endTime":"0","summary":"本次试验目的是评估不适合或拒绝化疗的EGFRm阳性III期不可切除NSCLC患者在放疗前使用奥希替尼作为诱导治疗及在放疗后继续使用奥希替尼直至疾病进展的有效性。甲磺酸奥希替尼片为化学药物，适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4568","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","LU1829250122.USD","LU2456880835.USD","III","BK4007","BK4588","AZN","BK4134","LU0109394709.USD","LU2417539215.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592134408","title":"港股異動 | 諾誠健華(09969)升逾4% 自研新型TYK2抑制劑ICP-332治療CSU獲批准開展II/III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592134408?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK1574","BK4134","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592973845","title":"新諾威(300765.SZ)子公司司庫奇尤單抗注射液III期臨床試驗獲得頂線分析數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592973845?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 15:45","pubTimestamp":1766043917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司的控股子公司石药集团巨石生物制药有限公司开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。有关详细数据将于后续学术会议及期刊上发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","III","BK4134","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592442959","title":"登頂《Nature》主刊 | 信爾美®（瑪仕度肽注射液，GCG/GLP-1雙靶減重降糖藥物）兩項III期臨床研究結果背靠背同步發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2592442959","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592442959?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016000,"startTime":"0","endTime":"0","summary":"此次论文通过《自然》加速预览机制得以快速上线，再次印证国际顶级期刊对于玛仕度肽两项重磅研究的认可。信达生物制药集团综合管线首席研发官钱镭博士表示：\"信尔美是全球首个获批上市的GCG/GLP-1双靶药物，目前减重和糖尿病适应症均已获批。继其减重注册研究今年五月份发表于《新英格兰杂志》后，本次两项降糖注册研究DREAMS-1和DREAMS-2的成果再次以背靠背形式同步登上《自然》杂志，并以加速预览形式发表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4849560_ZH49560_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","BK4134","LU2242644610.SGD","LU2097828631.EUR","IVBIY","GLP","BK4144","BK1589","BK1161","LU0502904849.HKD","LU2097828557.USD","BK1583","BK4590","III","LU0455707207.USD","LU2097828714.EUR","LU2097828474.EUR","01801","LU2097828805.USD","HK0000165453.HKD","LU1969619763.USD","LU2328871848.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592902308","title":"III期ARTISTRY-2研究達主要終點，吉利德新型HIV二聯療法展現潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902308","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902308?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 07:05","pubTimestamp":1766012717,"startTime":"0","endTime":"0","summary":"12月15日，吉利德宣布III期ARTISTRY-2研究取得积极顶线结果。吉利德计划将ARTISTRY研究的III期结果提交给监管机构，并将在未来的科学大会上公布详细数据。在ARTISTRY-2研究中，每日一次的单片复方方案BIC/LEN达到了主要成功标准，其疗效非劣于BIKTARVY。ARTISTRY-2的研究结果将与III期ARTISTRY-1研究的发现共同构成监管申报的基础。吉利德已于2025年11月公布了ARTISTRY-1的顶线结果，显示BIC/LEN组合耐受性良好，在疗效上非劣于多片式抗反转录病毒治疗方案。目前尚无治愈HIV或艾滋病的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218071039a6afa5d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE00BSNM7G36.USD","LU0109394709.USD","LU1066053197.SGD","BK4568","LU0289739699.SGD","BK4588","BK4583","LU2089984988.USD","SG9999015945.SGD","GILD","LU2087621335.USD","LU1674673691.USD","BK4585","LU1430594728.SGD","LU0114720955.EUR","IE00B3T34201.USD","LU0234570918.USD","BK4550","SG9999015952.SGD","SG9999015986.USD","BK4532","LU0823416689.USD","LU2324357040.USD","LU1778281490.HKD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066051498.USD","LU1674673428.USD","IE0002270589.USD","LU1585245621.USD","LU0058720904.USD","LU0320765992.SGD","SG9999015978.USD","LU0882574055.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","III","LU1839511570.USD","LU2468319806.SGD","LU1571399168.USD","BK4134","IE00B19Z3581.USD","BK4566","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591869882","title":"來凱醫藥-B(02105)：LAE002 (AFURESERTIB)針對HR+/HER2-局部晚期或轉移性乳腺癌的III期臨床試驗(AFFIRM-205)已完成入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2591869882","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591869882?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 08:17","pubTimestamp":1765757864,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已完成LAE002联合氟维司群针对治疗HR+/HER2-局部晚期或转移性乳腺癌伴随 PIK3CA/AKT1/PTEN基因改变患者的III期临床试验AFFIRM-205入组。III 期临床试验AFFIRM-205为一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。集团与齐鲁制药有限公司已于 2025年11月12日签订独家许可协议。根据许可协议的条款及条件，齐鲁制药获得在中国地区进行LAE002的研究、开发及商业化的独家许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4203","III","HR","BK4225","BK1161","02105","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591865967","title":"復星醫藥控股子公司酮洛芬貼劑獲准開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2591865967","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591865967?lang=zh_tw&edition=fundamental","pubTime":"2025-12-14 08:13","pubTimestamp":1765671185,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月12日发布公告，其控股子公司上海朝晖药业有限公司研发的酮洛芬贴剂，已获得国家药品监督管理局批准，将在中国境内开展III期临床试验。　　该事件的影响范围主要集中于复星医药集团及其控股子公司朝晖药业的研发管线推进，以及未来潜在的非甾体抗炎药外用贴剂市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251214/31864526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0187","BK0175","BK0196","BK1191","III","BK0060","BK0012","BK0028","BK0239","BK1515","BK4134","600196","BK0183","02196","BK0096","BK0188","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590062305","title":"2025年11月貴州省互聯網新聞信息服務單位新增、變更新聞信息服務許可事項","url":"https://stock-news.laohu8.com/highlight/detail?id=2590062305","media":"多彩贵州网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590062305?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 14:23","pubTimestamp":1765347780,"startTime":"0","endTime":"0","summary":"根据《互联网新闻信息服务管理规定》(国家互联网信息办公室令第1号)，通过互联网站、应用程序、论坛、博客、微博客、公众账号、即时通信工具、网络直播等形式向社会公众提供互联网新闻信息服务，应当取得互联网新闻信息服务许可。　　2025年11月，贵州省互联网信息办公室依法对相关单位提交的许可服务项新增、变更申请开展审批，同意有关许可服务项新增、变更事宜，现公示如下：一审：曹　轶二审：罗亚楠三审：李铁流\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-10/doc-inhahxmi0013868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III","160636","159792"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590316827","title":"【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發， 最佳MRD陰性完全緩解率超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316827","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316827?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:22","pubTimestamp":1765243320,"startTime":"0","endTime":"0","summary":"此次展示的POLARIS-1研究数据体现了耐立克在Ph+ ALL治疗领域的巨大潜力。数据显示，在诱导治疗3个周期内，耐立克联合低强度化疗在初治Ph+ ALL患者中的最佳微小残留病阴性率和MRD阴性完全缓解率分别为66.0%和64.2%；同时显示出良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842157_ZH42157_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","BK4588","BK4139","III","BK4134","BK4585","LU1571399168.USD","06855","BK4109","BK4533","ALL","LU0985320562.USD","ASH","LU1699723380.USD","LU2355687059.USD","LU2463526074.USD","AAPG","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590168783","title":"信達生物信美悦（匹康奇拜單抗注射液）一項新臨床III期研究（CLEAR-2）達成終點，為中重度銀屑病長期管理提供更優方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2590168783","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590168783?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 08:00","pubTimestamp":1765238400,"startTime":"0","endTime":"0","summary":"次要终点全面达成，匹康奇拜单抗季度给药可维持皮损清除与生活质量整体改善 此外，本研究次要疗效终点均顺利达成。匹康奇拜单抗有望为银屑病、溃疡性肠炎和其他自身免疫性疾病患者提供更有效、更长给药周期的治疗方案。信美悦获得NMPA批准适应症为：适合系统性治疗的中重度斑块状银屑病成人患者。此外，匹康奇拜单抗治疗青少年银屑病和成人银屑病关节炎等多项新临床研究正在开展中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4841267_ZH41267_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["HK0000165453.HKD","LU2488822045.USD","LU2328871848.SGD","BK1161","LU2097828714.EUR","LU2097828474.EUR","BK1583","BK1589","LU2097828631.EUR","LU0455707207.USD","01801","LU1969619763.USD","LU2242644610.SGD","BK4139","III","LU0502904849.HKD","LU2097828557.USD","BK4134","IVBIY","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589352213","title":"中慧生物-B(02627)：凍幹人用狂犬病疫苗(人二倍體細胞)的III期臨床試驗啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2589352213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589352213?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 17:13","pubTimestamp":1765185186,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，集团近期启动集团冻干人用狂犬病疫苗的III期临床试验。公司于2024年10月完成该在研疫苗的I期临床试验。狂犬病是由一种狂犬病病毒引起的严重病毒性疾病，可能导致意识模糊和渐进性瘫痪等严重症状。利用人二倍体细胞研制的狂犬病疫苗为世卫组织推荐的“金标准”狂犬病疫苗，具有强大的安全性。公司的在研狂犬病疫苗在已完成的I期临床试验中显示出良好的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK4134","02627","III","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589829615","title":"脱髮新藥III期成功；創新藥出海新模式誕生","url":"https://stock-news.laohu8.com/highlight/detail?id=2589829615","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589829615?lang=zh_tw&edition=fundamental","pubTime":"2025-12-06 17:01","pubTimestamp":1765011660,"startTime":"0","endTime":"0","summary":"科伦博泰与Crescent达成“双向授权”交易，中国创新药出海再添新玩法；雄激素脱发新药III期临床成功，预计明年申报上市；中国药品价格登记系统上线，面向企业和全球开放查询；默克中国宣布重要任命；FDA再现人事动荡……若Crescent近期发生控制权变更或与第三方签订分许可协议，科伦博泰亦有资格向Crescent收取额外款项。阅读详情>>研发动态雄激素脱发新药III期成功12月4日，Cosmo Pharmaceuticals宣布，Clascoterone用于治疗男性雄激素性脱发的两项关键III期试验中取得积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206170552a437ab11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206170552a437ab11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","III","SBHMY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589885635","title":"勁方醫藥-B(02595)：GFH375治療轉移性胰腺癌註冊性臨床試驗在首家研究中心啓動 為全球首個口服KRAS G12D抑制劑單藥對照化療III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2589885635","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589885635?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 08:16","pubTimestamp":1764893771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375治疗经治 KRAS G12D突变型转移性胰腺癌患者的注册性III期试验已在北京大学肿瘤医院启动。这项多中心、开放标签、随机对照的III期试验将在约40家中心开展，计划入组约320例既往接受至少一种标准系统性治疗的转移性胰腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4134","BK1574","02595","09939","BK1515","159938","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589985521","title":"亞盛醫藥-B(06855)耐立克®一線治療Ph+ ALL的全球註冊III期臨床研究獲美國FDA和歐洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589985521?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2355687059.USD","BK4107","BK4585","BK4588","AAPG","BK4081","EMA","III","LU0985320562.USD","BK4139","06855","LU1571399168.USD","BK4134","BK4533","LU1699723380.USD","BK1574","ALL","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588037958","title":"CSLM Digital Asset Acquisition Corp III, Ltd. (Nasdaq: KOYN) 與 First Digital Group Ltd. 宣佈就擬議業務合併簽署意向書，以此打造全球穩定幣與數字支付領軍企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037958","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588037958?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 19:30","pubTimestamp":1764675000,"startTime":"0","endTime":"0","summary":"公司成立于 2019 年，在 2022 年由总部位于直布罗陀的 First Digital Group Ltd. 完成重组。合并后，新公司计划加快 First Digital 的国际扩张速度，拓展其产品组合，并进一步完善其监管与合规体系。顾问 Cohen & Company Capital Markets 担任 First Digital 的独家资本市场及并购顾问。Loeb & Loeb LLP 担任 KOYN 的法律顾问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197723/0/zh-hans/CSLM-Digital-Asset-Acquisition-Corp-III-Ltd-Nasdaq-KOYN-%E4%B8%8E-First-Digital-Group-Ltd-%E5%AE%A3%E5%B8%83%E5%B0%B1%E6%8B%9F%E8%AE%AE%E4%B8%9A%E5%8A%A1%E5%90%88%E5%B9%B6%E7%AD%BE%E7%BD%B2%E6%84%8F%E5%90%91%E4%B9%A6-%E4%BB%A5%E6%AD%A4%E6%89%93%E9%80%A0%E5%85%A8%E7%90%83%E7%A8%B3%E5%AE%9A%E5%B8%81%E4%B8%8E%E6%95%B0%E5%AD%97%E6%94%AF%E4%BB%98%E9%A2%86%E5%86%9B%E4%BC%81%E4%B8%9A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107671.USD","LU1861220207.SGD","BK4134","DAAQ","LU1861217088.USD","LU0106831901.USD","BK4023","LU1668664300.SGD","CSLM","III","DAAQU","KOYN","LU1791807156.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2588701422","title":"君聖泰醫藥-B(02511)公布HTD1801與達格列淨的頭對頭III期臨床研究結果展現控糖優勢及心血管代謝優效獲益","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701422","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588701422?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 08:03","pubTimestamp":1764633831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B 发布公告，HTD1801在2型糖尿病患者中开展的与达格列净头对头的临床III期试验取得了积极的结果，试验达到主要终点，并在多项关键心血管代谢指标的改善上优于达格列净。试验数据再次验证，HTD1801靶向2型糖尿病发生及发展的根源性问题，实现更全面的心血管代谢综合获益。HTD1801具有良好的安全性与耐受性，严重不良事件的发生率为3.8%。君圣泰医药计划于今年内启动HTD1801项目的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02511","III","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586720005","title":"東誠藥業(002675.SZ)：氟[18F]思睿肽注射液完成III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2586720005","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586720005?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 17:27","pubTimestamp":1764322073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)公告，公司控股子公司烟台蓝纳成生物技术股份有限公司(简称“蓝纳成”)正在研发的氟[18F]思睿肽注射液是一种靶向PSMA的放射性体内诊断药物，适用于下述前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病灶的正电子发射断层扫描(PET)成像：拟接受初始根治性治疗，怀疑存在转移灶的前列腺癌患者;血清前列腺特异性抗原(PSA)水平升高，怀疑生化复发的前列腺癌患者。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002675","BK0239","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586219474","title":"港股異動 | 宜明昂科-B(01541)午後升逾9% IMM0306的III期臨床研究方案獲CDE許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2586219474","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586219474?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 13:52","pubTimestamp":1764222736,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)午后涨超9%，截至发稿，涨7.98%，报7.31港元，成交额1070.04万港元。消息面上，宜明昂科午间公告，公司已获得国家药监局药品审评中心批准IMM0306联合来那度胺治疗复发/难治性滤泡性淋巴瘤的III期临床研究方案，标志着复发/难治性滤泡性淋巴瘤创新疗法的发展加速。据悉，IMM0306是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子，可阻断“别吃我”信号，激活巨噬细胞和NK细胞，优先结合CD20而非CD47，有效消除恶性B细胞，同时将毒性降至最低，从而可改善治疗效果。公司拥有IMM0306的全球知识产权及商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1223082196.USD","01541","BK4134","LU1223083913.SGD","BK4017","LU1223082519.USD","CDE","III"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":159,"code":"91000000","status":"200"}]}}